



## Finances and funding At a glance



### Income 2017/18



### Growth



The ICR's income rose by **£16 million** in 2017/18, an increase of **13 per cent** over the previous financial year.

### Income

**£140m**

The Institute of Cancer Research, London, had a total income in 2017/18 of **£140.1 million**.



We received **£65.2 million** – around **47 per cent** of our income – from peer-reviewed research grants and industrial collaboration. Around **19 per cent** of our income came from Cancer Research UK, **6 per cent** from Breast Cancer Now and **2 per cent** from Wellcome.



As a college of the University of London, the ICR received **20 per cent** of its income from the Higher Education Funding Council for England - subsequently the Office for Students and UK Research and Innovation.

From a total of **£28.6 million**, **£18.1 million** funded research, **£9.3 million** funded capital projects and **£1.2 million** funded teaching.



We received **£27.9 million** – around **20 per cent** of our income – from royalties. Of this, we earned **£25.6 million** in royalties through sales of the prostate cancer drug abiraterone, which was discovered at the ICR.



The ICR also received a total of **£12.2 million**, around **9 per cent** of our total income, in legacies and donations, raised through our Development Office. Some **£3.6 million** of the total came from legacies and **£8.6 million** from donations.



The increase was driven by **£7 million** capital funding from the UK Research Partnership Investment Fund (UKRPIF) for the new Centre for Cancer Drug Discovery, growth in research funding from grants and contracts, and higher royalty income.

# Finances and funding

## Continued

### Expenditure



The ICR's total expenditure in 2017/18 was **£114.3 million**, a slight increase of 4.9 million compared with 2016/17.



We spent a total of **£108.1million**, or **95 per cent** of our total spend, on research activity. We spent **78 per cent** of our total spend on the direct costs of research and **17 per cent** on the support costs of research.